P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY

Detalles Bibliográficos
Autores principales: Einsele, H, Cohen, AD, Delforge, M, Hillengass, J, Goldschmidt, H, Weisel, K, Raab, M-S, Scheid, C, Schecter, JM, De Braganca, KC, Varsos, H, Yeh, T-M, Wang, L, Vogel, M, Corsale, C, Akram, M, Pacaud, L, Nesheiwat, T, Agha, M, Cohen, YC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012124/
http://dx.doi.org/10.1097/01.HS9.0000829604.35383.e8
_version_ 1784687736403263488
author Einsele, H
Cohen, AD
Delforge, M
Hillengass, J
Goldschmidt, H
Weisel, K
Raab, M-S
Scheid, C
Schecter, JM
De Braganca, KC
Varsos, H
Yeh, T-M
Wang, L
Vogel, M
Corsale, C
Akram, M
Pacaud, L
Nesheiwat, T
Agha, M
Cohen, YC
author_facet Einsele, H
Cohen, AD
Delforge, M
Hillengass, J
Goldschmidt, H
Weisel, K
Raab, M-S
Scheid, C
Schecter, JM
De Braganca, KC
Varsos, H
Yeh, T-M
Wang, L
Vogel, M
Corsale, C
Akram, M
Pacaud, L
Nesheiwat, T
Agha, M
Cohen, YC
author_sort Einsele, H
collection PubMed
description
format Online
Article
Text
id pubmed-9012124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-90121242022-04-18 P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY Einsele, H Cohen, AD Delforge, M Hillengass, J Goldschmidt, H Weisel, K Raab, M-S Scheid, C Schecter, JM De Braganca, KC Varsos, H Yeh, T-M Wang, L Vogel, M Corsale, C Akram, M Pacaud, L Nesheiwat, T Agha, M Cohen, YC Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9012124/ http://dx.doi.org/10.1097/01.HS9.0000829604.35383.e8 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Poster
Einsele, H
Cohen, AD
Delforge, M
Hillengass, J
Goldschmidt, H
Weisel, K
Raab, M-S
Scheid, C
Schecter, JM
De Braganca, KC
Varsos, H
Yeh, T-M
Wang, L
Vogel, M
Corsale, C
Akram, M
Pacaud, L
Nesheiwat, T
Agha, M
Cohen, YC
P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
title P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
title_full P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
title_fullStr P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
title_full_unstemmed P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
title_short P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
title_sort p08: cartitude-2 update: ciltacabtagene autoleucel, a b-cell maturation antigen–directed chimeric antigen receptor t-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy
topic Poster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012124/
http://dx.doi.org/10.1097/01.HS9.0000829604.35383.e8
work_keys_str_mv AT einseleh p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT cohenad p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT delforgem p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT hillengassj p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT goldschmidth p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT weiselk p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT raabms p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT scheidc p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT schecterjm p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT debragancakc p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT varsosh p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT yehtm p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT wangl p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT vogelm p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT corsalec p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT akramm p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT pacaudl p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT nesheiwatt p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT agham p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy
AT cohenyc p08cartitude2updateciltacabtageneautoleucelabcellmaturationantigendirectedchimericantigenreceptortcelltherapyinlenalidomiderefractorypatientswithprogressivemultiplemyelomaafter13priorlinesoftherapy

Ejemplares similares